Validation of exacerbation history grading by GOLD for predicting future COPD outcomes
<bold>Background:</bold> Individuals with COPD often experience exacerbations (ECOPD). For over a decade, high ECOPD risk is stratified according to a history of ≥2 moderate ECOPD and/or ≥1 severe ECOPD in <12 months. To date, these cutoffs lack validation. <bold>Objectives:</bold> To validate the ECOPD history frequency cutoff values suggested by GOLD, and to explore potential other cutoff strategies to predict ECOPD and all-cause mortality. <bold>Methods:</bold> Data from patients with COPD of the German COSYCONET cohort study were analyzed. Risk of ECOPD, hospitalizations and all-cause mortality during 4.5 years were assessed using binomial logistic regressions, and area under the ROC curves (AUC-ROC) with 95% confidence intervals (CI). <bold>Results:</bold> 2,291 patients with COPD GOLD 1-4 (mean age 65±8 years, 61% male, FEV1 53±19% predicted) were included. ECOPD history cutoff points by GOLD showed an AUC of 0.63 (95% CI 0.60-0.65) and 0.62 (95% CI 0.58-0.66) to predict ECOPD and hospitalizations, respectively. One previous ECOPD <12 months (AUC 0.66, 95% CI 0.64-0.69) more accurately predicted ECOPD and hospitalizations, and in line with GOLD, one previous hospitalization <12 months (AUC 0.63, 95% CI 0.60-0.67) predicted ECOPD and hospitalizations. The 4-year mortality rate was 9.6%. Patients with ≥3 previous ECOPD or ≥1 previous hospitalizations in <12 months were 2.18 (95% CI 1.27-3.72) and 1.57 (95% CI 1.29-1.91) times more likely to die, respectively. <bold>Conclusions:</bold> This study highlights the limited predictive performance of the current COPD risk assessment by GOLD. Novel cutoffs were suggested, categorizing patients as non-exacerbators or high-risk exacerbators based on a history of ≥1 ECOPD and/or ≥1 hospitalization <12 months.
Authors
- Sarah Houben‐Wilke (ORCID: https://orcid.org/0000-0001-6214-0365)
- Frits M.E. Franssen (ORCID: https://orcid.org/0000-0002-1633-6356)
- Peter J. Alter (ORCID: https://orcid.org/0000-0002-2115-1743)
- Martijn A. Spruit (ORCID: https://orcid.org/0000-0003-3822-7430)
- Rudolf A. Jörres (ORCID: https://orcid.org/0000-0002-9782-1117)
- Klaus F. Rabe (ORCID: https://orcid.org/0000-0002-7020-1401)
- Kiki Waeijen-Smit (ORCID: https://orcid.org/0000-0002-3737-7026)
- Robert Bals (ORCID: https://orcid.org/0000-0002-1472-9535)
- Tim Speicher
- Daphne Peerlings (ORCID: https://orcid.org/0000-0002-7449-4408)
- Claus Franz Vogelmeier (ORCID: https://orcid.org/0000-0002-9798-2527)
- Tobias Welte (ORCID: https://orcid.org/0000-0002-9947-7356)
- Henrik Watz
- Sami O. Simons (ORCID: https://orcid.org/0000-0002-4296-5076)
Institutions
- Philipps University of Marburg (DE)
- Maastricht University Medical Centre (NL)
- Maastricht University (NL)
- Medizinische Hochschule Hannover (DE)
- München Klinik (DE)
- German Center for Lung Research (DE)
- Ciro (NL)
- LungenClinic Grosshansdorf (DE)
- Saarland University (DE)
Publication Details
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1183/13993003.congress-2024.oa4647
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00